Bioxydyn has delivered multiple studies for pharmaceutical companies in the quantitative imaging of inflammation in a wide range of diseases, including rheumatoid arthritis and osteoarthritis.

We use dynamic contrast-enhanced MRI (DCE-MRI) to quantify changes in perfusion and endothelial integrity in the presence of inflammation and during treatment. Bioxydyn has defined many of the standard approaches to the technique’s implementation in clinical trials.

DCE-MRI involves the use of standard clinical intravenously-administered gadolinium-based contrast agents. The uptake and washout of the agent is interpreted using physiological modelling methods to provide imaging biomarkers of microvascular function and inflammation.

Bioxydyn uses the Ktrans quantitative biomarker which has SI units (min-1) and can be readily compared between centres. Its relationship to the intensity of inflammation is based on sound and widely accepted science, is extremely sensitive to drug effects, and only requires small patient numbers.

How can we help?

Contact us at